Large Pharma / Biotech Enterprise (>10,000 employees or >USD 1B revenue) Market Analysis

Molecular Biology Simulation Software Market to Reach USD 1.8B by 2033 at 9.2% CAGR

Top-20 pharma groups including Pfizer, Novartis and AstraZeneca are the highest-ACV buyers, running enterprise Schrödinger Suite, BIOVIA Discovery Studio, and in-house GROMACS/AMBER implementations on private HPC. Multi-year TCV deals in this segment can exceed USD 5M. The land-and-expand motion is most effective here, with module cross-sell (docking → FEP → ADMET) driving NRR above 120% for leading vendors (Claritas model).